-
The method of claim 1, wherein the antagonist is a peptide corresponding to the LRP-6 binding site of Dkk-1.
-
The method of claim 1, wherein the antagonist is peptide A as set forth in SEQ ID NO:11.
-
The method of claim 1, wherein the antagonist is an antibody that specifically binds Dkk-1.
-
A method of treating an osteolytic lesion in a mammal comprising administering to a mammal in need thereof an effective amount of a GSK3β inhibitor, wherein said GSK3β inhibitor mimics positive Wnt signaling.
-
The method of claim 8, wherein the GSK3β inhibitor is lithium chloride.
-
A method of enhancing osteogenesis in a mammal comprising administering to a mammal in need thereof an effective amount of a Dkk-1 antagonist, wherein said Dkk-1 antagonist inhibits Dkk-1 activity on the Wnt signaling pathway.
-
The method of claim 10, wherein said mammal is a human.
-
The method of claim 10, wherein the antagonist is directed to human Dkk-1.
-
The method of claim 10, wherein the antagonist comprises a peptide corresponding to the LRP-6 binding site of Dkk-1.
-
The method of claim 10, wherein the antagonist is peptide A as set forth in SEQ ID NO:11.
-
The method of claim 10, wherein the antagonist is an antibody that specifically binds Dkk-1.
Interesting…